Hemophilia

ASH has announced its three inaugural quality improvement champions.

The FDA approved marstacimab-hncq for treatment of certain individuals with hemophilia.

Efanesoctocog alfa prophylaxis exhibited high sustained factor VIII activity among younger children with severe hemophilia, according to findings published in The New England Journal of Medicine.

The FDA’s decision to approve a one-time gene therapy for adults with moderate to severe hemophilia B could have a considerable impact on the treatment landscape, according to a researcher involved in the pivotal trial for the agent.

The FDA approved fidanacogene elaparvovec-dzkt for treatment of adults with moderate to severe hemophilia B.

In this video interview with Healio, Lindsey A. George, MD, spoke about a session on factor VIII biochemistry presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Efanesoctocog alfa prophylaxis is conventionally cost-ineffective compared with standard factor VIII for patients with severe hemophilia A without inhibitors, according to results presented at ASH Annual Meeting and Exposition.

SAN DIEGO — Emicizumab exhibited efficacy for infants with severe hemophilia A without factor VIII inhibitors, according to study results presented at ASH Annual Meeting and Exposition.

Elderly individuals with moderate or severe hemophilia had poorer joint or functional status and greater joint pain sensitivity than those with mild hemophilia or healthy controls, according to study results.

Hemophilia death rates among men in the United States improved between 1999 and 2020, according to study results.